Patents by Inventor Sayda Mahgoub Elbashir
Sayda Mahgoub Elbashir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12070495Abstract: Provided herein are methods and compositions for inducing in a subject abroad neutralizing antibody response to human immunodeficiency virus (HIV) infection.Type: GrantFiled: March 13, 2020Date of Patent: August 27, 2024Assignees: ModernaTX, Inc., The United States of America, as represented by the Department of Health and Human ServicesInventors: Paolo Lusso, Peng Zhang, Elisabeth Narayanan, Sayda Mahgoub Elbashir
-
Publication number: 20230374079Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: August 4, 2023Publication date: November 23, 2023Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sayda Mahgoub Elbashir
-
Publication number: 20230346914Abstract: The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The RNA vaccines encode domains and subunits of coronavirus.Type: ApplicationFiled: February 6, 2021Publication date: November 2, 2023Applicant: ModernaTX, Inc.Inventors: Guillaume Stewart-Jones, Andrea Carfi, Sayda Mahgoub Elbashir, Mihir Metkar
-
Publication number: 20230338506Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: January 29, 2021Publication date: October 26, 2023Applicant: ModernaTX, Inc.Inventors: Christine Shaw, Guillaume Stewart-Jones, Elisabeth Narayanan, Vladimir Presnyak, Sayda Mahgoub Elbashir
-
Publication number: 20230303632Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: February 28, 2023Publication date: September 28, 2023Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sayda Mahgoub Elbashir
-
Patent number: 11643441Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.Type: GrantFiled: October 21, 2016Date of Patent: May 9, 2023Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sayda Mahgoub Elbashir
-
Publication number: 20230020362Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: May 5, 2022Publication date: January 19, 2023Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Publication number: 20220241399Abstract: Provided herein are methods and compositions for inducing in a subject abroad neutralizing antibody response to human immunodeficiency virus (HIV) infection.Type: ApplicationFiled: March 13, 2020Publication date: August 4, 2022Applicants: Moderna TX, Inc., The United States of America, as represented by the Department of Health and Human ServicesInventors: Paolo Lusso, Peng Zhang, Elisabeth Narayanan, Sayda Mahgoub Elbashir
-
Patent number: 11364292Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: GrantFiled: June 10, 2020Date of Patent: June 21, 2022Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Patent number: 11235052Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.Type: GrantFiled: April 21, 2020Date of Patent: February 1, 2022Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
-
Publication number: 20200368344Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: June 10, 2020Publication date: November 26, 2020Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Publication number: 20200299693Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.Type: ApplicationFiled: February 28, 2020Publication date: September 24, 2020Inventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
-
Publication number: 20200289639Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.Type: ApplicationFiled: April 21, 2020Publication date: September 17, 2020Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
-
Patent number: 10702597Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: GrantFiled: June 15, 2018Date of Patent: July 7, 2020Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Patent number: 10675342Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.Type: GrantFiled: September 20, 2018Date of Patent: June 9, 2020Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
-
Patent number: 10633656Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.Type: GrantFiled: December 22, 2016Date of Patent: April 28, 2020Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Whitehead Institute for Biomedical Research, UNIVERSITY OF MASSACHUSETTSInventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
-
Patent number: 10238731Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.Type: GrantFiled: August 11, 2017Date of Patent: March 26, 2019Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
-
Publication number: 20190008947Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.Type: ApplicationFiled: September 20, 2018Publication date: January 10, 2019Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
-
Publication number: 20180344839Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.Type: ApplicationFiled: June 15, 2018Publication date: December 6, 2018Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
-
Publication number: 20170327822Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.Type: ApplicationFiled: December 22, 2016Publication date: November 16, 2017Inventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel